复发性头颈部鳞状细胞癌中的 PD-L1 表达。
PD-L1 expression in recurrent head and neck squamous cell carcinoma.
机构信息
Radiation Oncology Department, University Hospital Morvan, 2 avenue Foch, 29200, Brest, France.
Department of Pathology, University Hospital Morvan, 2 avenue Foch, 29200, Brest, France.
出版信息
Eur Arch Otorhinolaryngol. 2022 Jan;279(1):343-351. doi: 10.1007/s00405-021-06777-7. Epub 2021 Apr 1.
PURPOSE
To evaluate the Programmed Cell Death Ligand (PD-L1) expression at diagnosis and relapse in patients with head and neck carcinoma (HNSCC) treated with radio(chemo)therapy.
METHODS
PD-L1 immunohistochemistry was performed in tumor cells (TC) and immune cells (IC) in 44 patients and scored as 0 = 0%, 1 = < 5%, 2 = 6-49% or 3 = ≥ 50% cells.
RESULTS
PD-L1 expression on TC before RT was scored as 0, 1, 2 and 3 in 28, 4, 8 and 4 patients, respectively. In 10 patients, IC did not show any PD-L1 expression; while in 8, 16, and 10 patients, PD-L1 expression was scored 1, 2 and 3, respectively. At relapse, 7/36 patients had a PD-L1 expression positivation in TC, while the opposite was observed in 6 patients. Overall, survival at 2 years was higher in patients with PD-L1 expression (90% versus 62.5%, p = 0.032).
CONCLUSION
PD-L1 expression may vary throughout the course of the disease. A re-evaluation of PD-L1 expression on biopsies at the time of recurrence should be recommended.
目的
评估接受放化疗的头颈部癌（HNSCC）患者在诊断和复发时程序性死亡配体 1（PD-L1）的表达。
方法
对 44 例患者的肿瘤细胞（TC）和免疫细胞（IC）进行 PD-L1 免疫组织化学染色，评分标准为 0=0%，1= <5%，2=6-49%或 3= ≥50%细胞。
结果
在 RT 前，TC 的 PD-L1 表达评分分别为 28、4、8 和 4 例患者的 0、1、2 和 3。在 10 例患者中，IC 未显示任何 PD-L1 表达；而在 8、16 和 10 例患者中，PD-L1 表达分别评分为 1、2 和 3。在复发时，36 例患者中有 7 例 TC 的 PD-L1 表达呈阳性，而 6 例患者相反。总的来说，PD-L1 表达患者的 2 年生存率更高（90%对 62.5%，p=0.032）。
结论
PD-L1 表达可能在疾病过程中发生变化。建议在复发时对活检进行 PD-L1 表达的重新评估。
Zotero 插件